SPRB Stock Financial Analysis - Spruce Biosciences, Inc. (OTCPK) Stock

Overview

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Spruce Biosciences, Inc. as of June 30, 2025 is 1.30 MM.
The operating income for Spruce Biosciences, Inc. as of June 30, 2025 is -50.67 MM.
The net income for Spruce Biosciences, Inc. as of June 30, 2025 is -48.34 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	1.30	-50.67	-48.34
2025-03-31	2.91	-58.01	-55.45
2024-12-31	4.91	-56.15	-53.04
2024-09-30	7.10	-43.24	-39.43
2024-06-30	9.57	-47.49	-43.11
2024-03-31	10.13	-51.43	-46.75
2023-12-31	10.09	-51.99	-47.92
2023-09-30	7.20	-52.94	-49.11
2023-06-30	4.13	-50.84	-48.16
2023-03-31	1.96	-48.75	-47.21
2022-12-31		-47.28	-46.18
2022-09-30		-44.31	-44.22
2022-06-30		-44.15	-44.27
2022-03-31		-43.98	-44.17
2021-12-31		-42.07	-42.29
2021-09-30		-41.27	-41.45
2021-06-30		-39.42	-39.59
2021-03-31		-34.10	-34.26
2020-12-31		-29.42	-29.54
2020-09-30		-24.21	-24.38

Income Statement: EPS

The earnings per share basic for Spruce Biosciences, Inc. as of June 30, 2025 is -84.75.
The earnings per share diluted for Spruce Biosciences, Inc. as of June 30, 2025 is -84.75.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-84.75	-84.75
2025-03-31	-99.08	-99.08
2024-12-31	-96.39
2024-09-30	-71.97	-71.97
2024-06-30	-78.96	-78.96
2024-03-31	-85.92	-85.92
2023-12-31	-93.32
2023-09-30	-107.69	-107.69
2023-06-30	-120.78	-120.78
2023-03-31	-138.15	-138.15
2022-12-31	-147.21
2022-09-30	-141.13	-141.13
2022-06-30	-141.55	-141.55
2022-03-31	-141.48	-141.48
2021-12-31	-135.78
2021-09-30	-135.67	-135.67
2021-06-30	-172.00	-172.00
2021-03-31	-221.09	-221.09
2020-12-31	-369.78
2020-09-30	-2,379.76	-2,379.76

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Spruce Biosciences, Inc. as of June 30, 2025 is -51.45 MM.
The cash from financing activities for Spruce Biosciences, Inc. as of June 30, 2025 is -1.84 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-51.45		-1.84
2025-03-31	-53.73		-1.81
2024-12-31	-55.96		-1.62
2024-09-30	-46.50	9.30	-1.55
2024-06-30	-49.54	23.29	-1.55
2024-03-31	-36.44	45.29	-1.62
2023-12-31	-33.27	55.78	49.14
2023-09-30	-33.80	61.05	49.73
2023-06-30	-30.11	30.16	50.04
2023-03-31	-41.65	41.67	50.38
2022-12-31	-41.68	23.69	-0.24
2022-09-30	-39.74	3.14	-0.11
2022-06-30	-38.76	7.70	-0.00
2022-03-31	-38.92	-86.64	0.27
2021-12-31	-35.88	-79.17	0.64
2021-09-30	-35.34	-73.21	94.76
2021-06-30	-35.34	-60.92	137.94
2021-03-31	-30.35	-0.09	137.66
2020-12-31	-27.52	-0.07	181.03
2020-09-30	-21.16	-0.05	88.75

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/e for Spruce Biosciences, Inc. as of June 30, 2025 is -0.06.
The p/book for Spruce Biosciences, Inc. as of June 30, 2025 is 0.22.
The p/tbv for Spruce Biosciences, Inc. as of June 30, 2025 is 0.22.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30	-0.06	0.22	0.22
2025-03-31		0.24	0.24
2024-12-31		0.34	0.34
2024-09-30	-0.42	0.31	0.31
2024-06-30	-0.47	0.33	0.33
2024-03-31		0.40	0.40
2023-12-31	-2.40	1.38	1.38
2023-09-30	-1.92	0.96	0.96
2023-06-30	-1.78	0.78	0.78
2023-03-31	-1.91	1.29
2022-12-31		0.33	0.33
2022-09-30		0.37	0.37
2022-06-30	-0.93	0.41	0.41
2022-03-31	-1.11	0.42	0.42
2021-12-31	-2.53	0.88	0.88
2021-09-30	-3.53	1.07	1.07
2021-06-30
2021-03-31	-1.20	0.29	0.29
2020-12-31	-1.39	0.28	0.28
2020-09-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Spruce Biosciences, Inc. as of June 30, 2025 is 2.66.
The ebit (3y)/ev for Spruce Biosciences, Inc. as of June 30, 2025 is 2.35.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	2.66	2.35
2025-03-31	0.86	0.97
2024-12-31	0.98	1.10
2024-09-30	0.88	0.93
2024-06-30	0.83	0.82
2024-03-31	0.77	0.73
2023-12-31	-2.14	-1.95
2023-09-30	51.25	46.83
2023-06-30	-3.18	-2.94
2023-03-31	-0.67	-0.60
2022-12-31	-4.86	-4.03
2022-09-30	4.74	3.93
2022-06-30	-1.97	-1.50
2022-03-31	-4.70	-3.38
2021-12-31	-0.81	-0.55
2021-09-30	-0.60	-0.32
2021-06-30
2021-03-31	-2.22	-1.27
2020-12-31	-7.49	-4.44
2020-09-30

Management Effectiveness

The roa for Spruce Biosciences, Inc. as of June 30, 2025 is -0.73.
The roe for Spruce Biosciences, Inc. as of June 30, 2025 is -0.94.
The roic for Spruce Biosciences, Inc. as of June 30, 2025 is -3.13.
The croic for Spruce Biosciences, Inc. as of June 30, 2025 is -3.13.
The ocroic for Spruce Biosciences, Inc. as of June 30, 2025 is -3.03.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.73	-0.94	-3.13	-3.13	-3.03
2025-03-31	-0.45	-0.59	-0.72	-0.71	-0.85
2024-12-31	-0.38	-0.52	-0.72	-0.71	-0.85
2024-09-30	-0.38	-0.50	-0.69	-0.44	-0.79
2024-06-30	-0.34	-0.43	-0.66	0.10	-0.51
2024-03-31	-0.56	-0.70	-0.59	0.88	-0.41
2023-12-31	-0.52	-0.63	-0.54	0.85	-0.37
2023-09-30	-0.46	-0.54	-0.47	0.49	-0.30
2023-06-30	-0.45	-0.53	-0.47	0.49	-0.29
2023-03-31	-0.40	-0.46	-0.41	0.44	-0.36
2022-12-31	-0.33	-0.37	-0.52	-0.43	-0.47
2022-09-30	-0.33	-0.37	-0.52	-0.43	-0.47
2022-06-30	-0.31	-0.34	-0.46	-0.33	-0.41
2022-03-31	-0.27	-0.30	-0.41	-1.17	-0.36
2021-12-31	-0.25	-0.28	-0.36	-0.97	-0.28
2021-09-30	-0.53	-0.62	-0.33	-0.11	-0.26
2021-06-30	-1.02	-1.35	-0.29	0.30	-0.26
2021-03-31	-7.30		-0.23	0.71	-0.20
2020-12-31	-6.30		-0.19	0.98	-0.18
2020-09-30		-11.78	-0.35	0.96	-0.30

Gross Margins

The gross margin for Spruce Biosciences, Inc. as of June 30, 2025 is -15.14.
The net margin for Spruce Biosciences, Inc. as of June 30, 2025 is -19.06.
The operating margin for Spruce Biosciences, Inc. as of June 30, 2025 is -19.94.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	-15.14	-19.06	-19.94
2025-03-31	-4.08	-5.55	-6.09
2024-12-31	-4.08	-5.55	-6.09
2024-09-30	-3.49	-4.50	-4.96
2024-06-30	-3.74	-4.62	-5.08
2024-03-31	-3.90	-4.75	-5.15
2023-12-31	4.66	-6.82	-7.35
2023-09-30	-0.76	-11.66	-12.31
2023-06-30	1.00	-11.66	-12.31
2023-03-31		-24.04	-24.82
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30